Regenerative Medicine and Stem Cells Technologies

If a new anti-cancer drug shows promise in a Petri dish, often the next step is to test the drugs effect in mice. This system tends to work well with drugs that directly target cancer, but breaks down with immunotherapies.

Researchers in the University of Georgias Regenerative Bioscience Center have succeeded in reproducing the effects of traumatic brain injury and stimulating recovery in neuron cells grown in a petri dish.

The master regulators of gut stem cells, called intestinal myofibroblasts, have pumps that protect them, and thus the gut, from the toxic effects of a wide range of compounds, including the anticancer drug tamoxifen, according to an investigation led by Duke-NUS Medical School.

Neuroscientist Dr. David Vilchez and his team at CECAD, the University of Colognes Cluster of Excellence for Aging Research, have made an important step toward understanding the mechanisms that cause the neurodegenerative disorder Huntingtons disease

Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells (CSCs). CSCs are related to cancer progression and dissemination, so its necessary to eradicate CSCs in order to cure cancer.

In what could be a major breakthrough in fighting prostate cancer, a researcher from Gitam Institute of Technology (GIT) has found that a drug used for treating coronary heart disease and stroke can control the progression of this form of cancer.

Keshav Singh, Ph.D., and colleagues have done just that, in a mouse model developed at the University of Alabama at Birmingham. When a mutation leading to mitochondrial dysfunction is induced, the mouse develops wrinkled skin and extensive, visible hair loss in a matter of weeks.

Circadian clocks are present in all cells of the body, and have a pervasive influence on all aspects of human physiology. This is because they regulate homeostasis by anticipating rhythmic changes in behavior and nutritional state, and by compartmentalizing incompatible metabolic pathways within precise temporal windows.

Implanted grafts, including vascular substitutes, inevitably experience remodeling by host cells. The design of grafts capable of promoting constructive remodeling remains a challenge within regenerative medicine.

At the end of June this year, the CAR-NK cell, a new immune cell, was reported as the third CAR cell to fight against cancer after CAR-T cells and CAR-macrophage cells.